Argatroban injection recalled in Class I action over particulate matter

The Food and Drug Administration has recorded a Class I recall of the injectable blood-thinner argatroban, after the manufacturer found foreign particles in the drug's solution. The agency logged the action in its enforcement database on 28 October 2026 and gave it the agency's most serious recall classification — the category reserved for defects that could cause serious injury or death [s1].

What is affected

The recall covers Argatroban Injection, USP, 250 mg/2.5 mL (100 mg/mL), supplied in single-dose vials and distributed nationwide [s1]. It spans two enforcement records. The larger, recall number D-0082-2027, covers 18,991 vials under NDC 42023-182-01; the smaller, D-0083-2027, covers 1,944 vials under NDC 42023-182-89 — nearly 21,000 vials in all [s1][s2]. The product is manufactured for Endo USA and distributed by Par Pharmaceutical, with Par Health USA, LLC named as the recalling firm [s1][s2]. The company began the recall itself on 13 October 2026, making this a voluntary, firm-initiated action, and the FDA records its status as ongoing [s1].

Why particulate matter in an injection matters

The enforcement record describes the reason directly: particulate matter identified as cellulose, polystyrene, polyethylene terephthalate, stainless steel, or stopper material found in the product solution [s1]. These are not trace impurities invisible to concern. Argatroban is given intravenously, straight into the bloodstream, and visible or sub-visible particles injected by that route can lodge in small vessels, seed clots, or trigger inflammatory and immune reactions. For a drug delivered by continuous infusion into critically ill patients, the margin for such contamination is essentially nil, which is why the agency's top classification fits.

The record documents the nature of the defect and the number of vials involved; it does not report patient harm, and the absence of such a report is not proof that none occurred [s1].

What argatroban is used for

Argatroban is a direct thrombin inhibitor — an anticoagulant that works by blocking thrombin, a central enzyme in clot formation. Its signature use is in patients who cannot receive heparin, most notably those with heparin-induced thrombocytopenia (HIT), a dangerous immune reaction in which heparin paradoxically triggers clotting and a falling platelet count. In that setting argatroban is often one of the few anticoagulants that can be used, and it is given in intensive-care and procedural settings where clotting must be controlled minute to minute. A recall of a drug used precisely because the alternatives are off the table carries a supply dimension as well as a safety one.

What it means in practice

This is a recall aimed at hospitals, pharmacies and the clinicians who stock and administer intravenous anticoagulants, not at the general public — argatroban is not a product anyone keeps at home [s1]. A Class I recall sets a concrete task for those handlers: identify whether any affected lots are in inventory, quarantine them, and follow the recalling firm's instructions for return or replacement [s1][s2]. The affected lots are listed by number in the enforcement records, with expiry dates running from October 2026 into 2027 [s1][s2].

Because argatroban is often the anticoagulant of choice when heparin cannot be used, pharmacies pulling affected stock also have to ensure a clean supply remains available for the patients who depend on it. That continuity — keeping a usable alternative on the shelf while contaminated vials come off it — is part of what a recall of a critical-care drug puts in motion [s1].

What to watch

Two things. First, whether the recall widens: enforcement records are updated as firms and the agency work through the affected lots, and the vial counts and lot lists are the authoritative detail [s1][s2]. Second, supply — argatroban's narrow role means a large recall can tighten availability for HIT patients even where no shortage is formally declared.

Red flags: this is an inventory action for health professionals, so there is no consumer shelf to check. Any patient who has received an intravenous anticoagulant and develops sudden breathlessness, chest pain, new swelling or signs of a clot should be assessed urgently by their care team. This article describes an FDA enforcement action and is not medical advice. Questions about anticoagulation for a particular patient are for the treating clinicians and hospital pharmacy.